CAS NO: | 27200-12-0 |
生物活性 | Dihydromyricetin is a potent inhibitor with anIC50of 48 μM ondihydropyrimidinase. Dihydromyricetin can activateautophagythrough inhibitingmTORsignaling. Dihydromyricetin suppresses the formation ofmTORcomplexes (mTORC1/2). Dihydromyricetin is also a potentinfluenza RNA-dependent RNA polymeraseinhibitor with anIC50of 22 μM. | ||||||||||||||||
IC50& Target[1][3] |
| ||||||||||||||||
体外研究 (In Vitro) | Dihydromyricetin, a flavonol, significantly inhibits the catalytic activities of dihydropyrimidinase toward both the natural substrate dihydrouracil and xenobiotic substrate 5-propyl-hydantoin. Dihydromyricetin exhibits a significant inhibitory effect on the activities of dihydropyrimidinase for both substrates, even more than Myricetin does. The IC50values of Dihydromyricetin for dihydropyrimidinase determined from the titration curves using Dihydrouracil and 5-propyl-hydantoin are 48±2 and 40±2 μM, respectively[1]. Dihydromyricetin (DHM) supplementation significantly reverses the increased phosphorylation of mTOR at Ser2448(p-mTOR) during D-gal administration, which suggests that Dihydromyricetin can activate autophagy through inhibiting mTOR signaling[2]. | ||||||||||||||||
体内研究 (In Vivo) | Changes in learning and memory capacity in rats administrated normal control group, D-gal group, D-gal+Dihydromyricetin (100 mg/kg) group, D-gal+Dihydromyricetin (200 mg/kg) group assessed by morris water maze (MWM) (n=10 per group). Dihydromyricetin (DHM) treatment significantly shortens the escape latency when compared with D-gal-induced model group[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 320.25 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C15H12O8 | ||||||||||||||||
CAS 号 | 27200-12-0 | ||||||||||||||||
中文名称 | 二氢杨梅素;白蔹素 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(312.26 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |